SGLT2i, ARNi And Diuretic Use In Patients With Heart Failure
Not Applicable
- Conditions
- Health Condition 1: I509- Heart failure, unspecified
- Registration Number
- CTRI/2024/07/071466
- Lead Sponsor
- GSM Institute of Pharmaceutical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age equal to or greater than 18 years old
EF lesser than or equal to 40 percent for HFrEF and EF greater than or equal to 50 percent for HFpEF with or without Type-2 diabetes mellitus
Initiation of SGLT2i
Prescribed a loop diuretic and sacubitril valsartan prior to the initiation of SGLT2i
Exclusion Criteria
Estimated glomerular filtration rate less than 20 mL per min per 1.73 meter square or undergoing dialysis
Chronic heart failure persisting for a minimum of 6 months, with an ejection fraction below 25 percent at the commencement of SGLT2 inhibitor therapy
Discontinuation of SGLT2 inhibitors
Inadequate data in the patient medical records
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in loop diuretic and sacubitril/valsartan doseTimepoint: Baseline and after dose alteration of loop diuretics, ARNi and SGLT2i
- Secondary Outcome Measures
Name Time Method Dose change in other diuretic medications, Clinical parameters: RFT, Hematocrit (%), NYHA classification, electrolytes levels, lipid levels, blood sugar levels, ADRs to medications during the study period, Discontinuation of SGLT2 inhibitors because of volume depletion, Discontinuation of SGLT2 inhibitors due to other adverse reactionsTimepoint: Baseline and after dose alteration of loop diuretics, ARNi and SGLT2i